Invited commentary: how far can epidemiologists get with statistical adjustment?

In 2002, the Women’s Health Initiative (WHI) clinical trial reported that combined estrogen-plus-progestin hormone therapy did not prevent coronary heart disease in women (1). Combined estrogen-plus-progestin therapy increased the risk of stroke by a factor of 1.4 on average and doubled the risk of venous thromboembolism. Observational research up to the time of the WHI suggested that the relative risk of coronary heart disease was 0.50–0.65 in hormone users compared with nonusers (2, 3). Based on observational research, the relative risk of stroke was considered less than or near 1.0 for hormone therapy (2). Both observational studies (4) and a randomized trial, the Heart Estrogen/progestin Replacement Study (HERS) (5), showed a relative risk of 1–2 for venous thromboembolism in hormone users. The WHI clinical trial joined a body of experimental evidence showing no effect of postmenopausal hormone therapy on coronary heart disease clinical endpoints or measures of subclinical coronary atherosclerosis (6–16). In 1998, the Heart Estrogen/progestin Replacement Study reported no beneficial effect of hormone therapy on morbidity or mortality from coronary heart disease in women with established coronary disease (6). Seven other randomized trials of the effect of hormone therapy on arterial disease endpoints published in 2000–2002 found no effect of hormone therapy (7–13). A 1997 meta-analysis of small randomized trials of hormone replacement found that hormone therapy did not prevent cardiovascular disease (14). Follow-up of participants in the Heart Estrogen/progestin Replacement Study (15) showed no benefit of hormone therapy for any cardiovascular endpoint. The estrogen-only arm of the WHI clinical trial was terminated early after showing that hormones did not prevent coronary heart disease (16). In this issue, Prentice et al. (17) report an analysis of data from the WHI clinical trial and the WHI observational study. The WHI clinical trial and observational study were conducted by the same group of researchers, in the same time frame, and had similar procedures for ascertaining and monitoring events. Prentice et al. explore the reasons for the differences in estimates of coronary heart disease, stroke, and venous thromboembolism risk for hormones between the WHI clinical trial and the observational study. They attempt to resolve the discrepancies by statistical adjustment.

[1]  W. Willett,et al.  Use of Postmenopausal Hormones and Risk of Myocardial Infarction , 1981, Circulation.

[2]  B Rosner,et al.  A prospective study of postmenopausal estrogen therapy and coronary heart disease. , 1985, The New England journal of medicine.

[3]  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991 .

[4]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .

[5]  Caroline S. Fox,et al.  Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women , 1992, Annals of Internal Medicine.

[6]  A. Bostom,et al.  Postmenopausal estrogen therapy and cardiovascular disease. , 1992, The New England journal of medicine.

[7]  Meyer Js,et al.  Lack of postmenopausal estrogen replacement therapy and the risk of dementia. , 1995 .

[8]  V. Henderson,et al.  Estrogen replacement therapy and risk of Alzheimer disease. , 1996, Archives of internal medicine.

[9]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[10]  B Rosner,et al.  Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. , 1996, The New England journal of medicine.

[11]  D. Rowland,et al.  Smoking and oestrogen-replacement therapy as protective factors for Alzheimer's disease , 1997, The Lancet.

[12]  K. McPherson,et al.  Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials , 1997, BMJ.

[13]  J. Manson,et al.  Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.

[14]  R. Brookmeyer,et al.  A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease , 1997, Neurology.

[15]  PROSPECTIVE STUDY OF EXOGENOUS HORMONES AND RISK OF PULMONARY EMBOLISM IN WOMEN , 1997 .

[16]  L. Amaducci,et al.  Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging , 1998, Neurology.

[17]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[18]  A. Hofman,et al.  Estrogen use and early onset Alzheimer's disease: a population-based study , 1999, Journal of neurology, neurosurgery, and psychiatry.

[19]  D. Herrington,et al.  The Heart and Estrogen/Progestin Replacement Study , 1999, Drugs & aging.

[20]  E G Tangalos,et al.  Postmenopausal estrogen replacement therapy and risk of AD , 1999, Neurology.

[21]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[22]  Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000 .

[23]  F. Speizer,et al.  A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease , 2000, Annals of Internal Medicine.

[24]  Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses’ Health Study , 2001 .

[25]  Robert Selzer,et al.  Estrogen in the Prevention of Atherosclerosis , 2001, Annals of Internal Medicine.

[26]  F. Grodstein,et al.  Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study , 2001, Annals of Internal Medicine.

[27]  S. Störk,et al.  Effect of Oral Postmenopausal Hormone Replacement on Progression of Atherosclerosis: A Randomized, Controlled Trial , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Effects of Estrogen Replacement on the Progression of Coronary-Artery Atherosclerosis , 2001 .

[29]  S. Azen,et al.  Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. , 2001, Annals of internal medicine.

[30]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[31]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[32]  H. Sox,et al.  Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease , 2002, Annals of Internal Medicine.

[33]  C. Furberg,et al.  Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart Disease: HERS B-Mode Substudy , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[34]  V. Beral,et al.  Evidence from randomised trials on the long-term effects of hormone replacement therapy , 2002, The Lancet.

[35]  P. Schofield,et al.  A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study , 2002, BJOG : an international journal of obstetrics and gynaecology.

[36]  N. Cherry,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[37]  V. Beral,et al.  Long-term effects of hormone replacement therapy , 2003, The Lancet.

[38]  K. Yaffe Hormone therapy and the brain: déjà vu all over again? , 2003, JAMA.

[39]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[40]  J. Hsia,et al.  Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. A randomized controlled trial , 2003 .

[41]  M. Stampfer Commentary: hormones and heart disease: do trials and observational studies address different questions? , 2004, International journal of epidemiology.

[42]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[43]  Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study , 2004 .

[44]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[45]  Ross L Prentice,et al.  Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. , 2005, American journal of epidemiology.

[46]  P. Bath,et al.  Association between hormone replacement therapy and subsequent stroke: a meta-analysis , 2005, BMJ : British Medical Journal.